The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases.
Ascorbic acid
Cancer
Complementary therapy
Intravenous vitamin C
Liposomal vitamin C
Oxidative stress
Vitamin C
Journal
Journal of applied biomedicine
ISSN: 1214-0287
Titre abrégé: J Appl Biomed
Pays: Poland
ID NLM: 101221755
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
06
11
2018
accepted:
07
02
2020
entrez:
15
12
2021
pubmed:
1
3
2020
medline:
1
3
2020
Statut:
ppublish
Résumé
Health status is determined by the balance of oxidants and antioxidants which protects healthy cells against the threat of internal and external risk factors. Antioxidants such as ascorbate (vitamin C, ascorbic acid) are of fundamental importance in this respect. Ascorbate neutralizes potential damage caused by cellular oxidative stress which may be the greatest risk of damage to healthy tissue. Cellular oxidative stress is mediated by external factors (e.g. psychological stress, physical exertion, drugs, various diseases, environmental pollution, preservatives, smoking, and alcohol) and internal factors (products of cellular metabolism including reactive oxygen species). When the products of oxidative stress are not sufficiently neutralized, healthy cells are at risk for both mitochondrial and DNA damage. In the short term, cell function may deteriorate, while an increased production of proinflammatory cytokines over time may lead to the development of chronic inflammatory changes and diseases, including cancer. Although pharmaceutical research continues to bring effective chemotherapeutic agents to the market, a limiting factor is often the normal tissue and organ toxicity of these substances, which leads to oxidative stress on healthy tissue. There is increasing interest and imperative to protect healthy tissues from the negative effects of radio-chemotherapeutic treatment. The action of ascorbate against the development of oxidative stress may justify its use not only in the prevention of carcinogenesis, but as a part of supportive or complementary therapy during treatment. Ascorbate (particularly when administered parentally at high doses) may have antioxidant effects that work to protect healthy cells and improve patient tolerability to some toxic radio-chemotherapy regimens. Additionally, ascorbate has demonstrated an immunomodulatory effect by supporting mechanisms essential to anti-tumor immunity. Intravenous administration of gram doses of vitamin C produce high plasma levels immediately, but the levels drop rapidly. Following oral vitamin C administration, plasma levels increase slowly to relatively low values, and then gradually decay. With an oral liposomal formulation, significantly higher levels are attainable than with standard oral formulations. Therefore, oral administration of liposomal vitamin C appears to be an optimal adjunct to intravenous administration. In this review, the basic mechanisms and clinical benefits of ascorbate as an antioxidant that may be useful as complementary therapy to chemotherapeutic regimens will be discussed.
Identifiants
pubmed: 34907706
doi: 10.32725/jab.2020.003
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Subventions
Organisme : NCI NIH HHS
ID : CA148062
Pays : United States
Organisme : NCI NIH HHS
ID : CA184051
Pays : United States
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Antunes F, Cadenas E (2000). Estimation of H2O2 gradients across biomembranes. FEBS Lett 475: 121-126. DOI: 10.1016/S0014-5793(00)01638-0.
pubmed: 10858501
doi: 10.1016/S0014-5793(00)01638-0
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. (2002). Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668.
Benfeitas R, Selvaggio G, Antunes F, Coelho P M, Salvador A (2014). Hydrogen peroxide metabolism and sensing in human erythrocytes: A validated kinetic model and reappraisal ofthe role of peroxiredoxin II. Free Radic Biol Med 74: 35-49. DOI: 10.1016/j.freeradbiomed.2014.06.007.
pubmed: 24952139
doi: 10.1016/j.freeradbiomed.2014.06.007
Chatterjee K, Zhang J, Honbo N, Karliner JS (2010). Doxorubicin cardiomyopathy. Cardiology 115: 155-162. DOI: 10.1159/000265166.
pubmed: 20016174
doi: 10.1159/000265166
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. (2005). Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609. DOI: 10.1073/pnas.0506390102.
pubmed: 16157892
doi: 10.1073/pnas.0506390102
Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. (2007). Ascorbate in pharmacologic concentrations: a pro-drug for selective delivery of ascorbate radical and hydrogen peroxide to extracellular fluid in vivo. Proc Natl Acad Sci USA 104: 8749-8754. DOI: 10.1073/pnas.0702854104.
pubmed: 17502596
doi: 10.1073/pnas.0702854104
Chiang CD, Song EJ, Yang VC, Chao CC (1994). Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J 301(Pt 3): 759-764. DOI: 10.1042/bj3010759.
pubmed: 7914401
doi: 10.1042/bj3010759
Cieslak JA, Cullen JJ (2015). Treatment of pancreatic cancer with pharmacological ascorbate. Curr Pharm Biotechnol 16: 759-770. DOI: 10.2174/138920101609150715135921.
pubmed: 26201606
doi: 10.2174/138920101609150715135921
Cvetkovic RS, Scott LJ (2005). Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65: 1005-1024. DOI: 10.2165/00003495-200565070-00008.
pubmed: 15892593
doi: 10.2165/00003495-200565070-00008
Dahl H, Degré M (1976). The effect of ascorbic acid on of human interferon and the antiviral activity in vitro. Acta Pathol Microbiol Scand B 84B: 280-284. DOI: 10.1111/j.1699-0463.1976.tb01938.x.
pubmed: 970135
doi: 10.1111/j.1699-0463.1976.tb01938.x
Dai J, Weinberg RS, Waxman S, Jing Y (1999). Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277.
doi: 10.1182/blood.V93.1.268
Diliberto EJ, Jr., Heckman GD, Daniels AJ (1983). Characterization of ascorbic acid transport by adrenomedullary chromaffin cells. Evidence for Na+-dependent co-transport. J Biol Chem 258: 12886-12894.
doi: 10.1016/S0021-9258(17)44054-3
Du J, Cullen JJ, Buettner GR (2012). Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophysica Acta 1826: 443-457. DOI: 10.1016/j.bbcan.2012.06.003.
pubmed: 22728050
doi: 10.1016/j.bbcan.2012.06.003
Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, et al. (2010). Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res 16: 509-520. DOI: 10.1158/1078-0432.CCR-09-1713.
pubmed: 20068072
doi: 10.1158/1078-0432.CCR-09-1713
Evans RM, Currie L, Campbell A (1982). The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. Br J Nutr 47: 473-482. DOI: 10.1079/bjn19820059.
pubmed: 7082619
doi: 10.1079/bjn19820059
Frei B, Lawson S (2008). Vitamin C and cancer revisited. Proc Natl Acad Sci USA 105: 11037-11038. DOI: 10.1073/pnas.0806433105.
pubmed: 18682554
doi: 10.1073/pnas.0806433105
Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, et al. (2014). Intravenous vitamin C and cancer: a systematic review. Integr Cancer Ther 13: 280-300. DOI: 10.1177/1534735414534463.
pubmed: 24867961
doi: 10.1177/1534735414534463
Goetzl EJ, Wasserman SI, Gigli I, Austen KF (1974). Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest 53: 813-818. DOI: 10.1172/JCI107620.
pubmed: 4273024
doi: 10.1172/JCI107620
Gonzalez MJ, Miranda-Massari JR (2014). New insights on vitamin C and cancer. Springer Verlag, New York.
doi: 10.1007/978-1-4939-1890-4
Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH (2001). Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805-813. DOI: 10.1182/blood.v98.3.805.
pubmed: 11468182
doi: 10.1182/blood.v98.3.805
Graumlich J, Ludden TM, Conry-Cantilena C, Cantilena LR, Jr.,Wang Y, Levine M (1997). Phamacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14: 1133-1139. DOI: 10.1023/a:1012186203165.
pubmed: 9327438
doi: 10.1023/a:1012186203165
Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB (2012). Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, andtherapy. Antioxid Redox Signal 16: 1295-1322. DOI: 10.1089/ars.2011.4414.
pubmed: 22117137
doi: 10.1089/ars.2011.4414
Hickey S, Roberts H (2013). Vitamin C and cancer: is there a use for oral vitamin C? J. Orthomol Med 28: 33-44.
Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, et al. (2015). High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. Plos One 10: e0120228. DOI: 10.1371/journal.pone.0120228.
pubmed: 25848948
doi: 10.1371/journal.pone.0120228
Holmannová D, Koláčková M, Krejsek J (2012). [Vitamin C and its physiological role with respect to the components of the immune system]. Vnitr Lek 58: 743-749.
pubmed: 23121060
Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, et al. (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis 30: 1987-1996. DOI: 10.1093/carcin/bgp158.
pubmed: 19638429
doi: 10.1093/carcin/bgp158
Karasavvas N, Carcamo JM, Stratis G, Golde DW (2005). Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105: 4004-4012. DOI: 10.1182/blood-2003-03-0772.
pubmed: 15677571
doi: 10.1182/blood-2003-03-0772
Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM (2006). Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176(4 Pt 1): 1642-1647. DOI: 10.1016/j.juro.2006.06.042.
pubmed: 16952707
doi: 10.1016/j.juro.2006.06.042
Kennedy DD, Tucker KL, Ladas ED, Rheingold SR, Blumberg J, Kelly KM (2004). Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr 79: 1029-1036. DOI: 10.1093/ajcn/79.6.1029.
pubmed: 15159233
doi: 10.1093/ajcn/79.6.1029
Klaunig JE, Kamendulis LM (2004). The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267. DOI: 10.1146/annurev.pharmtox.44.101802.121851.
pubmed: 14744246
doi: 10.1146/annurev.pharmtox.44.101802.121851
Klener P (2011). Základy klinické onkologie. In: Klener P (ed.). Vnitřní lékařství. Praha: Galén, pp. 77-104.
Klimant E, Wright H, Rubin D (2018). Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr Oncol 25: 39-148. DOI: 10.3747/co.25.3790.
pubmed: 29719430
doi: 10.3747/co.25.3790
Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW (1996). Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189. DOI: 10.1016/0304-3835(96)04212-7.
pubmed: 8635156
doi: 10.1016/0304-3835(96)04212-7
Lane DJ, Lawen A (2009). Ascorbate and plasma membrane electron transport - enzymes vs efflux. Free Radic Biol Med 47: 485-495. DOI: 10.1016/j.freeradbiomed.2009.06.003.
pubmed: 19501649
doi: 10.1016/j.freeradbiomed.2009.06.003
Lee WJ (2009). The prospects of vitamin C in cancer therapy. Immune Netw 9: 147-152. DOI: 10.4110/in.2009.9.5.147.
pubmed: 20157602
doi: 10.4110/in.2009.9.5.147
Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. (1996). Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93: 3704-3709. DOI: 10.1073/pnas.93.8.3704.
pubmed: 8623000
doi: 10.1073/pnas.93.8.3704
Lewin S (1976). Vitamin C: its molecular biology and medical potential. Academic Press, London, New York, San Francisco.
Li H, Tu H, Wang Y, Levine M (2012). Vitamin C in mouse and human red blood cells: an HPLC assay. Anal Biochem 426: 109-117. DOI: 10.1016/j.ab.2012.04.014.
pubmed: 22522059
doi: 10.1016/j.ab.2012.04.014
Lloyd JV, Davis PS, Emery H, Lander H (1972). Platelet ascorbic acid levels in normal subjects and in disease. J Clin Pathol 25: 478-483. DOI: 10.1136/jcp.25.6.478.
pubmed: 4504974
doi: 10.1136/jcp.25.6.478
Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q (2014). High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6: 222. DOI: 10.1126/scitranslmed.3007154.
pubmed: 24500406
doi: 10.1126/scitranslmed.3007154
MacDonald L, Thumser AE, Sharp P (2002). Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr 87: 97-100. DOI: 10.1079/BJN2001492.
pubmed: 11895172
doi: 10.1079/BJN2001492
Mayland CR, Bennett MI, Allan K (2005). Vitamin C deficiency in cancer patients. Palliat Med 19: 17-20. DOI: 10.1191/0269216305pm970oa.
pubmed: 15690864
doi: 10.1191/0269216305pm970oa
Mikirova N, Casciari J, Rogers A, Taylor P (2012). Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Translat Med 10: 189. DOI: 10.1186/1479-5876-10-189.
pubmed: 22963460
doi: 10.1186/1479-5876-10-189
Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, et al. (2012). Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7(1): e29794. DOI: 10.1371/journal.pone.0029794.
pubmed: 22272248
doi: 10.1371/journal.pone.0029794
Murphy MP (2009). How mitochondria produce reactive oxygen species. Biochem J 417(Pt 1): 1-13. DOI: 10.1042/BJ20081386.
pubmed: 19061483
doi: 10.1042/BJ20081386
National Cancer Institute. High-Dose Vitamin C (PDQ) - Health Professional Version (2019). [online] [cit. 2019-07-08]. Available from: https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq#section/all
Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ (2018). Systematic review of intravenous ascorbate in cancer clinical trials. Antioxidants 7: 89. DOI: 10.3390/antiox7070089.
pubmed: 30002308
doi: 10.3390/antiox7070089
Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF (2014). Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32: 3634-3642. DOI: 10.1200/JCO.2014.55.8437.
pubmed: 25267757
doi: 10.1200/JCO.2014.55.8437
Niraula S, Seruga B, Ocana A, Goldstein R, Tannock IF, Amir E (2012). The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30: 3012-3019. DOI: 10.1200/JCO.2011.40.3824.
pubmed: 22802313
doi: 10.1200/JCO.2011.40.3824
Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M (2010). Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE 5: e11414. DOI: 10.1371/journal.pone.0011414.
pubmed: 20628650
doi: 10.1371/journal.pone.0011414
Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-537. DOI: 10.7326/0003-4819-140-7-200404060-00010.
pubmed: 15068981
doi: 10.7326/0003-4819-140-7-200404060-00010
Parrow NL, Leshin JA, Levine M (2013). Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal 19: 2141-2156. DOI: 10.1089/ars.2013.5372.
pubmed: 23621620
doi: 10.1089/ars.2013.5372
Perez-Cruz I, Cárcamo JM, Golde DW (2007). Caspase-8 dependent TRAIL-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12: 225-234. DOI: 10.1007/s10495-006-0475-0.
pubmed: 17031493
doi: 10.1007/s10495-006-0475-0
Prasad KN, Sinha PK, Ramanujam M, Sakamoto A (1979). Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 76: 829-832. DOI: 10.1073/pnas.76.2.829.
pubmed: 284405
doi: 10.1073/pnas.76.2.829
Reddy VG, Khanna N, Singh N (2001). Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun 282: 409-415. DOI: 10.1006/bbrc.2001.4593.
pubmed: 11401473
doi: 10.1006/bbrc.2001.4593
Savini I, Catani MV, Arnone R, Rossi A, Frega G, Del Principe D, et al. (2007). Translational control of the ascorbic acid transporter SVCT2 in human platelets. Free Radic Biol Med 42: 608-616. DOI: 10.1016/j.freeradbiomed.2006.11.028.
pubmed: 17291984
doi: 10.1016/j.freeradbiomed.2006.11.028
Savini I, Rossi A, Pierro C, Avigliano L, Catani MV (2008). SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 34: 347-355. DOI: 10.1007/s00726-007-0555-7.
pubmed: 17541511
doi: 10.1007/s00726-007-0555-7
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furgan M, et al. (2017). O2.- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31: 1-14. DOI: 10.1016/j.ccell.2017.02.018.
pubmed: 28366679
doi: 10.1016/j.ccell.2017.02.018
Shakir DK, Rasul KI (2009). Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res 1: 8-12. DOI: 10.4021/jocmr2009.02.1225.
pubmed: 22505958
doi: 10.4021/jocmr2009.02.1225
Song EJ, Yang VC, Chiang CD, Chao CC (1995). Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line. Europ J Pharmacol 292: 119-125. DOI: 10.1016/0926-6917(95)90003-9.
pubmed: 7720783
doi: 10.1016/0926-6917(95)90003-9
Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1332. DOI: 10.1200/JCO.1997.15.4.1318.
pubmed: 9193323
doi: 10.1200/JCO.1997.15.4.1318
Swann JB, Smyth MJ (2007). Immune surveillance of tumors. J Clin Invest 117: 1137-1146. DOI: 10.1172/JCI31405.
pubmed: 17476343
doi: 10.1172/JCI31405
Takahashi H, Mizuno H, Yanagisawa A (2012). High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe 1: 49-53. DOI: 10.1016/j.pmu.2012.05.008.
doi: 10.1016/j.pmu.2012.05.008
Taper HS, de Gerlache J, Lans M, Roberfroid M (1987). Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 40: 575-579. DOI: 10.1002/ijc.2910400424.
pubmed: 3666992
doi: 10.1002/ijc.2910400424
Taper HS, Keyeux A, Roberfroid M (1996). Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 16: 499-503.
Vera JC, Rivas CI, Velasquez FV, Zhang RH, Concha II, Golde DW (1995). Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. J Biol Chem 270: 23706-23712. DOI: 10.1074/jbc.270.40.23706.
pubmed: 7559541
doi: 10.1074/jbc.270.40.23706
Verrax J, Calderon PB (2008). The controversial place of vitamin C in cancer treatment. Biochem Pharmacol 76: 1644-16452. DOI: 10.1016/j.bcp.2008.09.024.
pubmed: 18938145
doi: 10.1016/j.bcp.2008.09.024
Vissers MCM, Das AB (2018). Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front Physiol 9: 809. DOI: 10.3389/fphys.2018.00809.
pubmed: 30018566
doi: 10.3389/fphys.2018.00809
Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J (2011). Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo (Athens, Greece) 25: 983-990.
pubmed: 22021693
Wang X, Liu J, Yokoi I, Kohno M, Mori A (1992). Direct detection of circulating free radicals in the rat using electron spin resonance spectrometry. Free Radic Biol Med 12: 121-126. DOI: 10.1016/0891-5849(92)90005-2.
pubmed: 1313773
doi: 10.1016/0891-5849(92)90005-2
Welch RW, Bergsten P, Butler JD, Levine M (1993). Ascorbic acid accumulation and transport in human fibroblasts. Biochem J 294: 505-510. DOI: 10.1042/bj2940505.
pubmed: 8373364
doi: 10.1042/bj2940505
Welsh RM (1984). Natural killer cells and interferon. Crit Rev Immunol 5: 55-93.
pubmed: 6085941
Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TJ, et al. (2013). Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71: 765-775. DOI: 10.1007/s00280-013-2070-8.
pubmed: 23381814
doi: 10.1007/s00280-013-2070-8
Wintergerst ES, Maggini S, Hornig DH (2006). Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann Nutr Metab 50: 85-94. DOI: 10.1159/000090495.
pubmed: 16373990
doi: 10.1159/000090495
Yeom CH, Jung GC, Song KJ (2007). Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22: 7-11. DOI: 10.3346/jkms.2007.22.1.7.
pubmed: 17297243
doi: 10.3346/jkms.2007.22.1.7
Yu Y, Bae S, Kim H, Kim Y, Chu NB, Chu NK, et al. (2011). The anti-tumor activity of vitamin C via the increase of Fas (CD95) and MHC I expression on human stomach cancer cell line, SNU1. Immune Netw 11: 210-215. DOI: 10.4110/in.2011.11.4.210.
pubmed: 22039369
doi: 10.4110/in.2011.11.4.210
Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. (2015). Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350: 1391-1356. DOI: 10.1126/science.aaa5004.
pubmed: 26541605
doi: 10.1126/science.aaa5004
Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, et al. (2006). Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12: 273-280. DOI: 10.1158/1078-0432.CCR-05-0503.
pubmed: 16397052
doi: 10.1158/1078-0432.CCR-05-0503